Table 1.
Characteristics of studies.
| Author | Year | Major Treatment | Sample size |
Responders | Age (X or M, [range]) (Mean ± Sd) |
Gender (male/female) | EGFR mutation | Pathology | Perform status | Stage | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NSCLC | SCLC | Undefined | ||||||||||
| Zhou Z.[41] | 2021 | Bev_icp + cisplatin_icp | 43 | 38 | 62.43 ± 2.55 | 20/23 | NA | 43 | 0 | 0 | NA | ≥IV |
| Zhou Z. | 2021 | cisplatin_icp | 43 | 29 | 61.34 ± 2.68 | 21/22 | NA | 43 | 0 | 0 | NA | ≥IV |
| Du N.[42] | 2013 | Bev_icp + cisplatin_icp | 36 | 30 | X = 52.5, [66–82] | 19/17 | 15 | 36 | 0 | 0 | KPS > 60 | IV |
| Du N. | 2013 | cisplatin_icp | 34 | 17 | 19/15 | 16 | 34 | 0 | 0 | KPS > 60 | IV | |
| Zhu S.G.[43] | 2020 | anlotinib + cisplatin_icp | 32 | 27 | 52.62 ± 2.84 | 17/15 | NA | 31 | 0 | 0 | KPS > 70 | Advanced |
| Zhu S.G. | 2020 | cisplatin_icp | 32 | 19 | 50.08 ± 2.61 | 18/14 | NA | 31 | 0 | 0 | KPS > 70 | Advanced |
| Zheng W.H.[44] | 2020 | anlotinib + endostar_icp | 44 | 32 | M = 59, [30–75] | 32/12 | NA | 44 | 0 | 0 | ECOG ≤ 2 | NA |
| Zheng W.H. | 2020 | anlotinib + cisplatin_icp | 40 | 14 | M = 57, [28–76] | 34/6 | NA | 40 | 0 | 0 | ECOG ≤ 2 | NA |
| Yue K.[45] | 2018 | anlotinib + cisplatin_icp | 40 | 34 | 69.15 ± 5.33 [55–78] | 23/17 | NA | 33 | 0 | 7 | KPS > 70 | Advanced |
| Yue K. | 2018 | cisplatin_icp | 40 | 25 | 69.11 ± 5.25 [55–78] | 24/16 | NA | 34 | 0 | 6 | KPS > 70 | Advanced |
| Yang Y.[46] | 2020 | Bev_iv + pemetrexed_iv +cicplatin_iv |
32 | 29 | 60.01 ± 3.99 [51–70] | 20/12 | NA | 32 | 0 | 0 | ECOG ≤ 2 | ≥IIIB |
| Yang Y. | 2020 | pemetrexed_iv +cisplatin_iv |
33 | 20 | 59.89 ± 4.02 [50–69] | 21/12 | NA | 33 | 0 | 0 | ECOG ≤ 2 | ≥IIIB |
| Yan Y.H.[47] | 2015 | Bev_icp | 46 | 27 | 53.6 ± 11.3 | 20/26 | NA | 46 | 0 | 0 | NA | IV |
| Yan Y.H. | 2015 | cisplatin_icp | 46 | 10 | 55.1 ± 10.3 | 18/28 | NA | 46 | 0 | 0 | NA | IV |
| Xue D.F.[48] | 2017 | Bev_icp + cisplatin_icp | 41 | 38 | 58.21 ± 3.25 [42–71] | 23/18 | NA | 41 | 0 | 0 | NA | NA |
| Xue D.F. | 2017 | cisplatin_icp | 41 | 31 | 58.96 ± 3.43 [43–71] | 24/17 | NA | 41 | 0 | 0 | NA | NA |
| Xiao C.[49] | 2021 | Bev_icp + lobaplatin_icp | 29 | 24 | 66.7 ± 3.7 [64–75] | 16/13 | NA | 23 | 6 | 0 | KPS ≥ 70 | NA |
| Xiao C. | 2021 | lobaplatin_icp | 29 | 16 | 67.2 ± 4.1 [63–75] | 11/18 | NA | 21 | 8 | 0 | KPS ≥ 70 | NA |
| Wang X.L.[50] | 2021 | Bev_iv + carboplatin_iv +pemetrexed_iv |
42 | 38 | 45.26 ± 2.31 [20–56] | 26/16 | NA | 42 | 0 | 0 | KPS ≥ 60 | NA |
| Wang X.L. | 2021 | carboplatin_iv +pemetrexed_iv |
42 | 31 | 45.32 ± 2.26 [21–57] | 25/17 | NA | 42 | 0 | 0 | KPS ≥ 60 | NA |
| Wang K.[51] | 2018 | Bev_icp | 29 | 20 | 63.2 ± 4.5 [35–75] | 16/13 | NA | 23 | 6 | 0 | KPS > 50 | NA |
| Wang K. | 2018 | cisplatin_icp | 29 | 12 | 62.9 ± 5.3 [33–75] | 15/14 | NA | 25 | 4 | 0 | KPS > 50 | NA |
| Sun Z.J.[52] | 2018 | Bev_icp + gemcitabine_icp | 24 | 20 | 53.5 ± 4.5 | 14/10 | 0 | 24 | 0 | 0 | KPS ≥ 60 | ≥IV |
| Sun Z.J. | 2018 | gemcitabine_icp | 22 | 11 | 51.2 ± 5.6 | 12/10 | 0 | 22 | 0 | 0 | KPS ≥ 60 | ≥IV |
| Sun Y.[53] | 2021 | apatinib + paclitaxel_iv +carboplatin_iv |
25 | 16 | 65.21 ± 2.93 [63–74] | 13/12 | NA | 25 | 0 | 0 | NA | ≥IIIB |
| Sun Y. | 2021 | paclitaxel_iv +carboplatin_iv |
25 | 9 | 65.79 ± 4.07 [64–78] | 11/14 | NA | 25 | 0 | 0 | NA | ≥IIIB |
| Su Z.[54] | 2019 | apatinib + paclitaxel_iv +cisplatin_icp |
31 | 24 | M = 69, [42–75] | 26/5 | NA | 31 | 0 | 0 | KPS > 60 | NA |
| Su Z. | 2019 | paclitaxel_iv +cisplatin_icp |
30 | 16 | 23/7 | NA | 30 | 0 | 0 | KPS > 60 | NA | |
| Shi E.H.[55] | 2020 | apatinib + pemetrexed_iv +cisplatin_icp |
30 | 26 | 59.6 ± 5.8 [51–73] | 17/13 | 0 | 30 | 0 | 0 | NA | NA |
| Shi E.H. | 2020 | pemetrexed_iv +cisplatin_icp |
30 | 18 | 62.9 ± 5.1 [51–73] | 15/15 | 0 | 30 | 0 | 0 | NA | NA |
| Qu B.[56] | 2015 | Bev_icp + cisplatin_icp | 32 | 27 | X = 72.8, [65–76] | 19/13 | NA | 26 | 0 | 6 | KPS > 70 | NA |
| Qu B. | 2015 | cisplatin_icp | 31 | 19 | X = 73.9, [67–78] | 17/14 | NA | 28 | 0 | 3 | KPS > 70 | NA |
| Nie K.K.[58] | 2020 | Bev_icp | 21 | 16 | 62 ± 11 | 13/8 | 0 | 19 | 0 | 2 | ECOG ≤ 3 | IV |
| Nie K.K. | 2020 | Bev_iv | 22 | 14 | 62 ± 12 | 14/8 | 0 | 19 | 0 | 3 | ECOG ≤ 3 | IV |
| Liu H.P.[57] | 2016 | Bev_icp + pemetrexed_iv +cisplatin_icp |
42 | 35 | 62.37 ± 7.81 | 29/13 | NA | 42 | 0 | 0 | KPS > 60 | NA |
| Liu H.P. | 2016 | pemetrexed_iv +cisplatin_icp |
42 | 27 | 61.42 ± 8.47 | 31/11 | NA | 42 | 0 | 0 | KPS > 60 | NA |
| Liang Y.[59] | 2021 | Bev_iv + pemetrexed_iv +carboplatin_iv |
41 | 36 | 43.25 ± 2.23 | 17/24 | NA | 41 | 0 | 0 | KPS > 70 | NA |
| Liang Y. | 2021 | pemetrexed_iv +carboplatin_iv |
41 | 27 | 43.42 ± 2.17 | 18/23 | NA | 41 | 0 | 0 | KPS > 70 | NA |
| Li Y.L.[60] | 2018 | Bev_iv + pemetrexed_iv +cisplatin_iv |
43 | 32 | 45.24 ± 21.38 [23–63] | 24/19 | NA | 43 | 0 | 0 | NA | NA |
| Li Y.L. | 2018 | pemetrexed_iv +cisplatin_iv |
43 | 22 | 43.28 ± 19.39 [26–57] | 27/16 | NA | 43 | 0 | 0 | NA | NA |
| Ke H.[61] | 2019 | Bev_iv + pemetrexed_iv +carboplatin_iv |
46 | 33 | 45.3 ± 2.1 [18–55] | NA | NA | 46 | 0 | 0 | KPS > 70 | NA |
| Ke H. | 2019 | pemetrexed_iv +carboplatin_iv |
46 | 29 | 46.17 ± 2.04 [19–56] | NA | NA | 46 | 0 | 0 | KPS > 70 | NA |
| Jiang Q.L.[62] | 2021 | Bev_iv + gemcitabine_iv +cisplatin_iv |
30 | 28 | 48.14 ± 2.52 [20–75] | 20/10 | NA | 30 | 0 | 0 | KPS > 60 | NA |
| Jiang Q.L. | 2021 | gemcitabine_iv +cisplatin_iv |
30 | 17 | 47.52 ± 2.38 [20–75] | 19/11 | NA | 30 | 0 | 0 | KPS > 60 | NA |
| Huang P.C.[63] | 2021 | Bev_iv + pemetrexed_iv +carboplatin_iv |
46 | 20 | 39.28 ± 4.77 [27–65] | 25/21 | 0 | 46 | 0 | 0 | ECOG ≤ 2 | ≥III |
| Huang P.C. | 2021 | Bev_icp + pemetrexed_iv +carboplatin_iv |
46 | 30 | 40.17 ± 5.03 [25–67] | 27/19 | 0 | 46 | 0 | 0 | ECOG ≤ 2 | ≥III |
| Huang B.[64] | 2016 | Bev_icp | 37 | 30 | 60.28 ± 6.17 [54–72] | 26/11 | 0 | 37 | 0 | 0 | KPS > 70 | IV |
| Huang B. | 2016 | cisplatin_icp | 36 | 21 | 61.31 ± 6.05 [55–74] | 27/9 | 0 | 36 | 0 | 0 | KPS > 70 | IV |
| Ge F.C.[65] | 2020 | anlotinib + nedaplatin_icp | 37 | 21 | 67.23 ± 4.73 [49–79] | 17/20 | NA | 31 | 0 | 6 | KPS > 70 | Advanced |
| Ge F.C. | 2020 | nedaplatin_icp | 31 | 7 | 68.26 ± 4.68 [50–77] | 16/15 | NA | 26 | 0 | 5 | KPS > 70 | Advanced |
| Cui X.X.[66] | 2019 | Bev_icp + cisplatin_icp | 10 | 8 | 50.2 ± 9.8 [40–60] | 6/4 | NA | NA | NA | NA | NA | NA |
| Cui X.X. | 2019 | Cisplatin_icp | 10 | 5 | 49.4 ± 8.6 [40–60] | 5/5 | NA | NA | NA | NA | NA | NA |
| Chen Z.B.[67] | 2019 | anlotinib + cisplatin_icp | 25 | 23 | 60.12 ± 3.18 [60–81] | 13/12 | NA | NA | 0 | 3 | KPS > 70 | Advanced |
| Chen Z.B. | 2019 | cisplatin_icp | 25 | 13 | 71.07 ± 2.21 [71–80] | 14/11 | NA | NA | 0 | KPS > 70 | Advanced | |
| Chen Y.X.[68] | 2020 | Bev_icp + carboplatin_icp | 21 | 19 | X = 60.67, [45–72] | 14/7 | NA | 21 | 0 | 0 | BIS > 60 | NA |
| Chen Y.X. | 2020 | Carboplatin_icp | 21 | 13 | X = 60.17, [48–73] | 15/6 | NA | 21 | 0 | 0 | BIS > 60 | NA |
| Chen T.J.[69] | 2016 | Bev_icp + cisplatin_icp | 24 | 20 | 54.6 ± 7.7 [41–74] | NA | NA | 24 | 0 | 0 | NA | NA |
| Chen T.J. | 2016 | cisplatin_icp | 24 | 13 | NA | NA | 24 | 0 | 0 | NA | NA | |
| Bi L.Q.[70] | 2020 | anlotinib | 30 | 20 | M = 65.1, [40–75] | 18/12 | NA | 30 | 0 | 0 | KPS ≥ 60 | ≥III |
| Bi L.Q. | 2020 | placebo | 30 | 13 | M = 63.2, [38–75] | 17/13 | NA | 30 | 0 | 0 | KPS ≥ 60 | ≥III |
| Bai M.[71] | 2017 | Bev_icp + cisplatin_icp | 43 | 39 | 60.14 ± 6.20 | 23/20 | NA | 43 | 0 | 0 | NA | NA |
| Bai M. | 2017 | cisplatin_icp | 43 | 31 | 60.23 ± 6.18 | 22/21 | NA | 43 | 0 | 0 | NA | NA |
Bev = bevacizumab, BIS = barthel index score, ECOG = Eastern Cooperative Oncology Group score, EGFR = epidermal growth factor receptor, icp = intracavitary perfusionm, iv = intravenous injection, KPS = Karnofsky score, M = median age, NA = not available, Sd = standard error, X = mean age.